235106-53-3

Basic information

• Product Name: Imidazo[1,2-a]pyridin-6-amine (9CI)
• Synonyms: Imidazo[1,2-a]pyridin-6-amine (9CI);Imidazo[1,2-a]pyridin-6-amine;H-imidazo[1,2-a]pyridin-6-amine
• CAS NO: 235106-53-3
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15058
• Product Categories: AMINETERTIARY;Building Blocks;Imidazo[x,x-y]pyridine
• Mol File: 235106-53-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.32 g/cm³
• Refractive Index: 1.696
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: Imidazo[1,2-a]pyridin-6-amine (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridin-6-amine (9CI)(235106-53-3)
• EPA Substance Registry System: Imidazo[1,2-a]pyridin-6-amine (9CI)(235106-53-3)

Safety Data

• Hazardous Substances Data: 235106-53-3(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridin-6-amine (9CI) is a chemical compound with the molecular formula C8H7N3. It is a heterocyclic amine with a fused imidazo-pyridine ring structure. It is commonly used in medicinal chemistry as a building block for the synthesis of various pharmaceutical compounds due to its unique structural properties. Imidazo[1,2-a]pyridin-6-amine (9CI) has potential therapeutic applications in the treatment of various diseases and conditions, including cancer and neurological disorders. Its pharmacological properties and potential therapeutic uses make it a significant compound in drug discovery and development.

InChI:InChI=1/C7H7N3/c8-6-1-2-7-9-3-4-10(7)5-6/h1-5H,8H2

Upstream product

• 25045-82-3 6-nitroimidazo[1,2-a]pyridine 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 

Downstream Products

• 421595-97-3 7-ethyl-8-methylimidazo[1,2-a][1,5]naphthyridine 
• 421595-88-2 C₂₅H₂₀N₃P 
• 1257857-59-2 phenyl imidazo[1,2-a]pyridin-6-ylcarbamate 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.